logo-loader
viewNetscientific PLC

NetScientific says portfolio company, Vortex BioSciences, to present “compelling new data” at AACR

The transatlantic healthcare IP commercialisation group said the studies support the use of Vortex's non-invasive technology in the characterisation of circulating tumour cells (CTCs) for important clinical biomarkers, namely EGFR and PD-L1

Cancer cells
Biomarkers play a pivotal role in the development and progression of certain cancer in patients with non-small cell lung cancer

Netscientific PLC (LON:NSCI) announced that its US-based portfolio company, Vortex BioSciences, a leading liquid biopsy company, is to present "compelling new data" at the American Association for Cancer Research (AACR) Annual Meeting bring held in Chicago from 14  April to 18 April 2018.

The transatlantic healthcare IP commercialisation group said the studies support the use of Vortex's non-invasive technology in the characterisation of circulating tumour cells (CTCs) for important clinical biomarkers, namely EGFR and PD-L1.

WATCH: Netscientific PLC raises £5mln to speed up portfolio commercialisation

The firm said these biomarkers play a pivotal role in the development and progression of certain cancer in patients with non-small cell lung cancer (NSCLC).

Commenting on the news, Francois Martelet, Vortex BioSciences’ chairman and CEO of NetScientific said: "The studies presented underscore the potential use of Vortex's technology in the diagnosis and treatment of cancer patients.

“It is paramount to understand which patients are likely to exhibit a superior response to targeted therapies in order to determine the best treatment algorithm, as well as to contain healthcare expenditure.

“We firmly believe that Vortex's technology can play an instrumental role in this."

Quick facts: Netscientific PLC

Price: 6 GBX

AIM:NSCI
Market: AIM
Market Cap: £4.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read